CA2480121C - Methods for increasing polypeptide production - Google Patents

Methods for increasing polypeptide production Download PDF

Info

Publication number
CA2480121C
CA2480121C CA2480121A CA2480121A CA2480121C CA 2480121 C CA2480121 C CA 2480121C CA 2480121 A CA2480121 A CA 2480121A CA 2480121 A CA2480121 A CA 2480121A CA 2480121 C CA2480121 C CA 2480121C
Authority
CA
Canada
Prior art keywords
millimolar
polypeptide
concentration
temperature
cell line
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2480121A
Other languages
English (en)
French (fr)
Other versions
CA2480121A1 (en
Inventor
Kirk P. Van Ness
Michael T. Trentalange
Bradley D. Dell
Jeffrey T. Mcgrew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Priority to CA2762016A priority Critical patent/CA2762016C/en
Publication of CA2480121A1 publication Critical patent/CA2480121A1/en
Application granted granted Critical
Publication of CA2480121C publication Critical patent/CA2480121C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2480121A 2002-03-27 2003-03-27 Methods for increasing polypeptide production Expired - Fee Related CA2480121C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2762016A CA2762016C (en) 2002-03-27 2003-03-27 Methods for increasing polypeptide production

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36824802P 2002-03-27 2002-03-27
US36824602P 2002-03-27 2002-03-27
US60/368,246 2002-03-27
US60/368,248 2002-03-27
PCT/US2003/009266 WO2003083066A2 (en) 2002-03-27 2003-03-27 Methods for increasing polypeptide production

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2762016A Division CA2762016C (en) 2002-03-27 2003-03-27 Methods for increasing polypeptide production

Publications (2)

Publication Number Publication Date
CA2480121A1 CA2480121A1 (en) 2003-10-09
CA2480121C true CA2480121C (en) 2012-02-28

Family

ID=28678222

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2480121A Expired - Fee Related CA2480121C (en) 2002-03-27 2003-03-27 Methods for increasing polypeptide production

Country Status (9)

Country Link
US (2) US6872549B2 (US06872549-20050329-C00002.png)
EP (1) EP1497444B1 (US06872549-20050329-C00002.png)
JP (3) JP2005521401A (US06872549-20050329-C00002.png)
AU (1) AU2003220529B2 (US06872549-20050329-C00002.png)
CA (1) CA2480121C (US06872549-20050329-C00002.png)
ES (1) ES2557741T3 (US06872549-20050329-C00002.png)
MX (1) MXPA04009381A (US06872549-20050329-C00002.png)
PL (1) PL376821A1 (US06872549-20050329-C00002.png)
WO (1) WO2003083066A2 (US06872549-20050329-C00002.png)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050005310A1 (en) * 1999-07-12 2005-01-06 Genentech, Inc. Expression vectors and methods
PL376821A1 (pl) * 2002-03-27 2006-01-09 Immunex Corporation Sposoby zwiększania produkcji polipeptydów
JP2006512061A (ja) * 2002-11-14 2006-04-13 ジェネンテック・インコーポレーテッド イントロン融合コンストラクトおよび高発現産生細胞系を選択するための使用方法
AU2004234377A1 (en) * 2003-04-25 2004-11-11 Immunex Corporation Inducers of recombinant protein expression
AU2004266043B2 (en) * 2003-08-21 2007-09-20 Duchesnay Inc. Micronutrient supplement
JP4520987B2 (ja) * 2003-08-21 2010-08-11 デュシェネ インク チャイルドプルーフ微量栄養素サプリメント
EP1697414A2 (en) * 2003-12-23 2006-09-06 Applied Research Systems ARS Holding N.V. Process for the production of tumor necrosis factor-binding proteins
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
WO2007049567A1 (ja) * 2005-10-24 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. 物質の製造方法
PL2253644T3 (pl) 2005-12-20 2014-04-30 Bristol Myers Squibb Co Kompozycje i sposoby wytwarzania kompozycji
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
WO2008029281A2 (en) * 2006-02-10 2008-03-13 Invitrogen Corporation Labeling and detection of post translationally modified proteins
US8247187B2 (en) * 2006-08-14 2012-08-21 Biocontrol Systems, Inc. Method for detecting pathogens
AU2007294731B2 (en) * 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW200907062A (en) * 2007-03-28 2009-02-16 Medarex Inc Methods of gene amplification and expression
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20090023186A1 (en) * 2007-07-22 2009-01-22 Excellgene Sa Use of valproic acid for enhancing production of recombinant proteins in mammalian cells
JP2011512877A (ja) * 2008-03-12 2011-04-28 ワイス・エルエルシー 組換えタンパク質の大スケール産生に適した細胞を同定する方法
CA2782320A1 (en) * 2009-12-02 2011-06-09 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life of fc fusion proteins
WO2012043754A1 (ja) 2010-09-30 2012-04-05 ダイキン工業株式会社 ドリップ防止剤、並びに、樹脂組成物
RU2615448C2 (ru) * 2010-12-28 2017-04-04 Чугаи Сейяку Кабусики Кайся Описание способа культивирования животной клетки
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
CN107988166B (zh) 2011-07-01 2022-03-15 美国安进公司 哺乳动物细胞培养
EP2653548A1 (de) 2012-04-17 2013-10-23 Greenovation Biotech GmbH Verfahren zur Erhöhung der Sekretion rekombinanter Proteine
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CA2904639A1 (en) * 2013-03-15 2014-09-25 Theocorp Holding Company, Llc Theobromine compositions useful for increasing fetal weight gain and enhancing bone properties
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
BR112019007858A2 (pt) 2016-10-21 2019-07-02 Amgen Inc formulações farmacêuticas e métodos para produzir as mesmas
KR102190790B1 (ko) * 2018-10-19 2020-12-15 주식회사 프로젠 변형된 egf 단백질의 생산 방법
US11339197B2 (en) 2017-10-23 2022-05-24 Progen Co., Ltd. Modified EGF protein, production method therefor, and use thereof
JP2024503239A (ja) 2020-12-22 2024-01-25 アムジェン インコーポレイテッド 細胞培養法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3824286A (en) 1970-07-07 1974-07-16 Lever Brothers Ltd Preparation of polyacetylalkylene diamines
DE2961658D1 (en) 1978-05-17 1982-02-18 Thomae Gmbh Dr K Process for preparing human interferon
US4301249A (en) * 1980-07-23 1981-11-17 Merck & Co., Inc. High titer production of hepatitis A virus
US4357422A (en) 1980-08-14 1982-11-02 Massachusetts Institute Of Technology Method of enhancing interferon production
US4416986A (en) * 1981-01-16 1983-11-22 Merck & Co., Inc. Methods of producing HBsAg
US4473647A (en) 1981-02-27 1984-09-25 Amf Inc. Tissue culture medium
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4992472A (en) 1987-06-16 1991-02-12 The United States Of America As Represented By The Department Of Health And Human Services Chemical differentiating agents
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5055608A (en) 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5330744A (en) 1988-11-14 1994-07-19 Sloan-Kettering Institute For Cancer Research Method for increasing sensitivity to chemically induced terminal differentiation
ZA899421B (en) 1988-12-14 1990-09-26 Merrell Dow Pharma Method of potentiating natural killer cell activity
CA2018228C (en) 1989-06-05 1996-02-27 Nancy L. Parenteau Cell culture systems and media
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
DE69332981T2 (de) 1992-10-23 2004-05-19 Immunex Corp., Seattle Methoden zur herstellung löslicher, oligomerer proteine
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US20010010922A1 (en) 1994-06-09 2001-08-02 Riccardo Dalla-Favera Cloning and uses of the genetic locus bcl-6
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
ES2253753T3 (es) 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
WO1998028010A2 (en) 1996-12-24 1998-07-02 Hyal Pharmaceutical Corporation Use of moieties for binding to hyaluronan and icam-1
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999032605A1 (en) 1997-12-19 1999-07-01 Novo Nordisk A/S Method for producing heterologous proteins in eukaryotic cells on an industrial scale using nucleotide-manipulating agents
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
EP1117778A2 (en) 1998-10-02 2001-07-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1171615B1 (en) 1999-04-26 2006-12-13 Genentech, Inc. Cell culture process for glycoproteins
ES2252070T3 (es) 1999-10-13 2006-05-16 Immunex Corporation Vectores y procedimientos para la expresion de proteinas recombinantes.
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
AU2001259432B2 (en) 2000-05-03 2005-04-21 Amgen Inc. Modified peptides, comprising an FC domain, as therapeutic agents
PL376821A1 (pl) * 2002-03-27 2006-01-09 Immunex Corporation Sposoby zwiększania produkcji polipeptydów

Also Published As

Publication number Publication date
ES2557741T3 (es) 2016-01-28
US20030211579A1 (en) 2003-11-13
WO2003083066A3 (en) 2004-02-26
JP4414472B2 (ja) 2010-02-10
PL376821A1 (pl) 2006-01-09
CA2480121A1 (en) 2003-10-09
AU2003220529B2 (en) 2006-09-07
EP1497444B1 (en) 2015-11-04
MXPA04009381A (es) 2005-01-25
US7452695B2 (en) 2008-11-18
WO2003083066A2 (en) 2003-10-09
JP4414466B2 (ja) 2010-02-10
EP1497444A2 (en) 2005-01-19
US20050233415A1 (en) 2005-10-20
JP2005521401A (ja) 2005-07-21
EP1497444A4 (en) 2006-08-30
AU2003220529A1 (en) 2003-10-13
US6872549B2 (en) 2005-03-29
JP2008167760A (ja) 2008-07-24
JP2009082138A (ja) 2009-04-23

Similar Documents

Publication Publication Date Title
CA2480121C (en) Methods for increasing polypeptide production
US20200080049A1 (en) Feed media
JP4510938B2 (ja) 哺乳動物細胞により産生されるタンパク質のシアル酸付加を調節する方法および培地
US20040265964A1 (en) Inducers of recombinant protein expression
CA2762016C (en) Methods for increasing polypeptide production

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831